|
WO2020227072A1
|
|
Cd33-binding polypeptides and uses thereof
|
|
US2020347139A1
|
|
CLEC12a Binding Polypeptides and Uses Thereof
|
|
US2020347142A1
|
|
CD123-Binding Polypeptides and Uses Thereof
|
|
WO2020146221A1
|
|
Polypeptides comprising modified il-2 polypeptides and uses thereof
|
|
WO2020077257A1
|
|
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
TW202028246A
|
|
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
CA3114693A1
|
|
5t4 single domain antibodies and therapeutic compositions thereof
|
|
CA3115089A1
|
|
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
AU2019321490A1
|
|
Ox40-binding polypeptides and uses thereof
|
|
US2020048350A1
|
|
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
SG11202009804RA
|
|
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
|
|
AU2018250641A1
|
|
Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
|
|
AU2017207742A1
|
|
Multivalent and multispecific 41BB-binding fusion proteins
|
|
SG11201805422WA
|
|
Multivalent and multispecific ox40-binding fusion proteins
|
|
AU2016297249A1
|
|
Multivalent and multispecific GITR-binding fusion proteins
|
|
AU2016257751A1
|
|
Type III secretion system targeting molecules
|
|
RS59159B1
|
|
Cd47 antibodies and methods of use thereof
|
|
KR20210032558A
|
|
Serpin fusion polypeptides and methods of use thereof
|
